Zotiraciclib
![]() | |
Clinical data | |
---|---|
Other names | TG02, SB1317 |
Routes of administration | By mouth |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | >99%[1] |
Metabolism | CYP3A4, CYP1A2[1] |
Identifiers | |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C23H24N4O |
Molar mass | 372.472 g·mol−1 |
3D model (JSmol) | |
Zotiraciclib (TG02) is a potent oral spectrum selective[clarification needed][2] kinase inhibitor for the treatment of cancer. It was discovered in Singapore by S*BIO Pte Ltd and falls under the category of small molecule macrocycles. It crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9).[3] It is one of a number of CDK inhibitors under investigation; others targeting CDK9 for the treatment of acute myeloid leukemia include alvocidib and .[4][5] Myc overexpression is a known factor in many cancers, with 80 percent of glioblastomas characterized by this property.[6] Zotiraciclib has been granted orphan drug designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of gliomas.[7][8]
As of January 2020, zotiraciclib is being evaluated by in two separate Phase 1b clinical trials for the treatment of glioblastoma multiforme (GBM). Zotiracicib is also being developed as a potential treatment for diffuse intrinsic pontine glioma (DIPG), a rare pediatric cancer. Both forms of brain cancer are characterized by Myc overexpression.[6]
Development[]
The first Phase 1b clinical trial of zotiraciclib in GBM, sponsored by the National Cancer Institute (NCI), is a multi-arm, dose-finding study examining zotiraciclib plus dose-dense or metronomic temozolomide (TMZ) in adults with recurrent anaplastic astrocytoma and GBM.[9]
Zotiraciclib is also being explored for the treatment of DIPG, a rare pediatric cancer.[citation needed]
References[]
- ^ Jump up to: a b Pasha MK, Jayaraman R, Reddy VP, Yeo P, Goh E, Williams A, et al. (March 2012). "Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor". Drug Metabolism Letters. 6 (1): 33–42. doi:10.2174/187231212800229336. PMID 22372550.
- ^ William AD et al. Discovery of Kinase Spectrum Selective Macrocycle (16E)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer. Journal of Medicinal Chemistry (2012), 55(1), 169-196.PMID: 22148278 DOI: 10.1021/jm201112g
- ^ Su YT, Chen R, Wang H, Song H, Zhang Q, Chen LY, et al. (March 2018). "Novel Targeting of Transcription and Metabolism in Glioblastoma". Clinical Cancer Research. 24 (5): 1124–1137. doi:10.1158/1078-0432.CCR-17-2032. PMC 8108069. PMID 29254993.
- ^ Blachly JS, Byrd JC, Grever M (April 2016). "Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia". Seminars in Oncology. 43 (2): 265–73. doi:10.1053/j.seminoncol.2016.02.003. PMID 27040705.
- ^ Lyle L, Daver N (August 2018). "Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway". The American Journal of Managed Care. 24 (16 Suppl): S356–S365. PMID 30132679.
- ^ Jump up to: a b Annibali D, Whitfield JR, Favuzzi E, Jauset T, Serrano E, Cuartas I, et al. (August 2014). "Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis". Nature Communications. 5 (4632): 4632. Bibcode:2014NatCo...5.4632A. doi:10.1038/ncomms5632. PMC 4143920. PMID 25130259.
- ^ "FDA grants orphan drug designation to zotiraciclib for the treatment of glioma". Center for Cancer Research. Cancer Research Center. 2020-01-09.
- ^ "EU/3/19/2202". European Medicines Agency. 2020-01-21.
- ^ Clinical trial number NCT02942264 for "Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma" at ClinicalTrials.gov
- Drugs not assigned an ATC code
- Protein kinase inhibitors